Mindfulness based interventions in multiple sclerosis - a systematic review

Robert Simpson1*, Jo Booth2, Maggie Lawrence2, Sharon Byrne1, Frances Mair1 and Stewart Mercer1

Abstract

Background: Multiple sclerosis (MS) is a stressful condition; depression, anxiety, pain and fatigue are all common problems. Mindfulness based interventions (MBIs) mitigate stress and prevent relapse in depression and are increasingly being used in healthcare. However, there are currently no systematic reviews of MBIs in people with MS. This review aims to evaluate the effectiveness of MBIs in people with MS.

Methods: Systematic searches were carried out in seven major databases, using both subject headings and key words. Papers were screened, data extracted, quality appraised, and analysed by two reviewers independently, using predefined criteria. Study quality was assessed using the Cochrane Collaboration risk of bias tool. Perceived stress was the primary outcome. Secondary outcomes include mental health, physical health, quality of life, and health service utilisation. Statistical meta-analysis was not possible. Disagreements were adjudicated by a third party reviewer.

Results: Three studies (n = 183 participants) were included in the final analysis. The studies were undertaken in Wales (n = 16, randomised controlled trial - (RCT)), Switzerland (n = 150, RCT), and the United States (n = 17, controlled trial). 146 (80%) participants were female; mean age (SD) was 48.6 (9.4) years. Relapsing remitting MS was the main diagnostic category (n = 123, 67%); 43 (26%) had secondary progressive disease; and the remainder were unspecified. MBIs lasted 6–8 weeks; attrition rates were variable (5-43%); all employed pre- post- measures; two had longer follow up; one at 3, and one at 6 months. Socio-economic status of participants was not made explicit; health service utilisation and costs were not reported. No study reported on perceived stress. All studies reported quality of life (QOL), mental health (anxiety and depression), physical (fatigue, standing balance, pain), and psychosocial measures. Statistically significant beneficial effects relating to QOL, mental health, and selected physical health measures were sustained at 3- and 6- month follow up.

Conclusion: From the limited data available, MBIs may benefit some MS patients in terms of QOL, mental health, and some physical health measures. Further studies are needed to clarify how MBIs might best serve the MS population.

Keywords: Multiple sclerosis, Mindfulness, Stress management

Background

Multiple sclerosis (MS) is a chronic, unpredictable, and poorly understood neurodegenerative inflammatory condition [1]. Nervous system damage can be extensive, with severe disability in both physical and cognitive realms [2,3]. Worldwide incidence of MS is increasing, with rates at 3.6/100,000 person-years in females and 2.0/100,000 person-years in men [4]. MS can present in myriad different ways and carries a high degree of uncertainty, in terms of disease progression and resultant impairment [5-7]. MS characteristically falls into several different diagnostic subclassifications, depending on disease activity and stage of progression [8,9].

MS typically follows a chronic and eventually progressive course. Consequently, health service utilisation costs accumulate and impact significantly on resource allocation [10]. Epidemiological data from the United States, Canada, and China all highlight comorbidity as problematic [11-14], with mental health diagnoses frequently co-existing. The
literature demonstrates anxiety and depression point prevalence estimates of up to 16.5% and 46%, respectively [15]. Health related quality of life (HRQOL) is often significantly impaired in people with MS [16], and may be exacerbated by disease uncertainty [5] and depression [13]. Mental health comorbidity is thought to be under-reported in people with MS [15,17] and is associated with diminished treatment adherence, increased somatic symptoms, and impairment of both functional ability, and social status [18]. As in many chronic illnesses, self-efficacy is of importance in people with MS. Enhanced feelings of control and acceptance may lessen the psychological and emotional impact of living with a chronic condition, and contribute to improvements in clinical status, such as diminished fatigue [19,20].

Psychological distress may contribute to MS disease activity [21], and a growing body of research evidence examines this hypothesis [22,23]. Cognitive behavioural therapy (CBT) has already been found to impact positively upon psychological distress [24] and pathological neuroimaging markers; the short term effect size for such CBT interventions has been shown in one study to rival that of certain disease modifying pharmacological agents [22].

**Why is it important to undertake a review of MBIs?**

The mitigation of stress is proposed as a means to actively manage and reduce pathological disease activity in people with MS [22]. Indeed, a CBT intervention has already demonstrated efficacy, reducing gadolinium lesion enhancement on neuroimaging during the active period of treatment. However, this effect is not sustained on cessation of therapist input [22]. MBIs are thought to operate in a different manner to CBT [36] and might have a more sustained effect, given the strong emphasis on regular self-practice. To date and as far as we are aware, no systematic review of the evidence for MBIs in people with MS has been published. This paper aims to evaluate the effectiveness of MBIs in people with MS.

**Methods**

**Search strategy**

In May 2013 a systematic search for published and unpublished studies was conducted in six major electronic bibliographic databases: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, Allied and Complementary Medicine Database, and PsychINFO. To identify any additional published and/or unpublished trials, we also searched ProQuest Dissertations & Theses Database and contacted MS/mindfulness researchers. Selected medical subject headings were combined with key words relating to MS and mindfulness to create a search strategy which was finalised for use in MEDLINE (see Additional file 1) and amended for use in the other databases, using appropriate controlled vocabulary, Boolean operators, and search symbols. Delimiters were: dates searched (1980–2013); research subjects (human); and language (English). The search included the grey literature, using reference lists and citation searching from reviews and published trials, the Science Citation Index, and also involved consulting noted experts in the field. Endnote was used to store and manage the results of the database searches.

**Selection criteria**

Studies were selected for inclusion using criteria related to the Study design, Participants, Interventions, and Outcomes model (SPIO). SPIO is an adapted version of PICO(a) (Population, Interventions, Comparison, and Outcomes) [37]. Any definite diagnosis of MS in an adult (>18 years) was acceptable for inclusion in the review. MBIs can vary by both name and range of ingredients; therefore a core content of: breath awareness, body awareness, and dynamic yoga postures (mindful movement) [34] taught in groups over 8 weeks. Mindfulness Based Cognitive Therapy (MBCT) is a derivative of MBSR, with a greater emphasis on cognitive techniques, designed for specific mental health conditions such as recurrent depression [35].
Selection of papers for inclusion
The bibliographic records identified by the searches were screened for relevance using broad inclusion criteria, i.e. ‘multiple sclerosis’ and ‘mindfulness’. All relevant papers were then screened, using the SPIO inclusion criteria (Table 1), to select eligible papers. All selected papers were subject to methodological appraisal. As the search yielded low numbers, a decision was made not to exclude studies solely on the basis of poor methodological quality. Screening methods were based on the Systematic Reviews guidance outlined in the Centre for Reviews and Dissemination (CRD) [38]. Methodological issues are discussed below and reported in the evidence table (Table 2).

Quality appraisal
Risk of bias was assessed using the Cochrane Collaboration’s assessment tool [39] to summarise the risk of bias for major outcomes. The evidence for each individual outcome was graded as low, unclear, or high risk. This included assessing for evidence of: sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; selective outcome reporting; and any other sources of bias.

Data extraction
The authors developed a data extraction tool, adapted from a previous systematic review examining the benefits of MBIs following transient ischaemic attack and stroke [29]. The data extracted included information on study design and methodology, the populations under review, the interventions being employed, and the outcomes recorded in each study. Two reviewers working independently carried out screening and data extraction. Broad screening was undertaken by RS and SB; narrow screening by RS and JB. Any disagreements were adjudicated via a further reviewer (SM).

Table 1 SPIO narrow screen inclusion/exclusion criteria

| Study design          | Inclusion criteria                                      | Exclusion criteria                             |
|-----------------------|--------------------------------------------------------|------------------------------------------------|
| Randomised controlled | Qualitative studies                                     | <18 years old Diseases other than (and not including) MS |
| trial, controlled trial| Systematic reviews                                      | Peri-Neuropathy                                 |
|                       | Literature reviews                                      |                                                 |
|                       | Guidelines Audit                                        |                                                 |
| Population            | Age >18 years Any diagnosis of MS                       |                                                 |
|                       | <18 years old Diseases other than (and not including) MS|                                                 |
| Intervention          | Any specifically mindfulness-based intervention (MBI)   | Psychotherapy Drug treatments Manual therapy (ie massage) |
| Outcomes              | Perceived stress Anxiety                                |                                                 |
|                       | Depression                                             |                                                 |
|                       | HRQOL                                                  |                                                 |
|                       | Pain                                                   |                                                 |
|                       | Personal wellbeing                                     |                                                 |
|                       | Social participation                                   |                                                 |
awareness or ‘scanning’. The MBIs were group based in 2 of the studies, but the Mills and Allen [41] intervention was delivered one to one.

Grossman et al. [40] used certified and experienced MBI teachers to deliver the MBI over 8 weekly 2.5 hour sessions, with a 7 hour session at week 6. They emphasised mindfulness practices in the sitting, lying and yoga asana postures, and also encouraged ‘homework’ practices for 40 minutes daily. They were the only investigators to record homework practice times. Tavee et al. [42] delivered a 4 hour introductory group session, followed by 8 weekly 1.5 hour classes, with a Buddhist Monk teaching all of the course components, including Samatha meditation (sitting and observing the breath), and mindful movement in the form of Tai Chi/Qi Gong and walking meditation. Tavee et al. [42] encouraged home practice, but did not record frequencies. Mills and Allen [41] delivered six individualised sessions in which unspecified teachers taught mindful movement with Tai Chi/Qi Gong, with breath and posture awareness, whilst encouraging participants to cultivate compassionate feelings towards themselves. Mills and Allen [41] also provided self study material, but did not report on participant uptake and usage by participants. Please see Table 2.

**Participant characteristics**

None of the studies provided data regarding ethnicity of participants. Across the three studies, 80% (n = 146) of participants were female, and the mean (SD) age of the total sample (n = 183) was 48.6 (9.4) years. Data regarding socioeconomic status was generally not well reported; for example, Mills and Allen [41] provided data on only half of their study population, of whom, 50% were in employment. Grossman et al. [40] recorded number of years in education. Disease phenotype was described in two of the studies; however, Tavee et al. [42] simply described participants (n = 17) as having any diagnosis of MS. From the remaining 166 patients where a phenotype could be discerned, 123 (67%) had a diagnosis of relapsing remitting MS, and the other 43 (25%) were diagnosed with secondary progressive MS. All three studies excluded patients with significant cognitive impairment, as well as those with severe physical disability, according to either the Expanded Disability Status Scale being >6 (requiring 2 walking aids i.e. a pair of canes, crutches, etc. - in order to walk about 20 meters, without resting), or more generally, being unable to make their own way to the hospital (Mills and Allen [41]). See Table 3.

**Outcomes**

The primary outcome sought by this review (perceived stress) was not reported in any of the studies. However, secondary outcomes of interest included: anxiety, depression, HRQOL, concentration, fatigue, vitality and general wellbeing. No information was available on economic parameters, such as cost/benefit analysis for patients, or health service utilisation. Please see Table 2.

**Mental health outcomes**

**Anxiety**

Grossman et al. [40] measured anxiety directly with the Spielberger Trait Anxiety Index (STAI), demonstrating significant reduction immediately post completion in...
Table 3 Participant characteristics

|                          | Mills and Allen [41] | Grossman et al. [40] | Tavee et al. [42] |
|--------------------------|-----------------------|----------------------|-------------------|
| Ethnicity                | NR                    | NR                   | NR                |
| Number of participants (% female) | 16 (80%)          | 150 (80%)            | 17 (78%)          |
| Mean age (SD)            | 49.8 (6.8)            | 47.3 (10.3)          | 48.7 (11.2)       |
| Socio-economic status    | NR                    | NR                   | NR                |
| Employment status        | 4 employed (25%)      | NR                   | NR                |
| Mean years of education (SD) | NR                  | 14.1 (1.9)           | NR                |
| Disease phenotype        | SP 16 (100%)          | RR 123 (82%)         | SP 27 (18%)       |
| Stage in disease progression | NR                  | Mean EDSS 3.0 (1.1)  | Mean EDSS 3.0 (2.5) |
| Comorbidities            | NR                    | NR                   | NR                |
| Number of patients on disease modifying medication | NR              | 91 (60.1%)           | NR                |
| Number of patients on psychotropic medication | NR             | 30 (20%)             | NR                |

1. SP - Secondary Progressive; 2. RR - Relapsing Remitting; 3. EDSS - Expanded disability status scale; 4. NR - Not recorded.
both whole intervention group and in further subgroup analyses of those with evidence of pre-intervention impairment. This was maintained at six-month follow up in overall group and subgroup analyses. Mills and Allen [41] included data on change in anxiety scores via a general MS symptom checklist, and the Profile of Mood States (POMS), reporting non-significant change. Please refer to Table 4.

**Depression**
Two studies assessed the effect of MBIs on depression. Grossman et al. [40] used the Center for Epidemiological Studies Depression (CES-D) scale, reporting significant reductions in both whole intervention group and subgroup analyses of those with pre-intervention impairment at intervention completion. This was maintained at six-month follow up in the overall group and in subgroup analyses. Mills and Allen [41] also reported a significant change using the POMS scale. See Table 4.

**Physical outcomes**

**Standing balance**
Mills and Allen [41] reported preferentially on physical measures, opting to focus on single-leg standing balance, with significant improvement noted at both study completion and at three-month follow up, although one participant’s data was missing for this latter calculation. Please see Table 5.

**Pain**
At study completion, Tavee et al. [42] described a significant reduction in bodily pain, as measured by the Visual Analogue Scale (VAS). See Table 5.

**Fatigue**
All three studies measured the effect of MBIs on fatigue. Scores on the Modified Fatigue Impact Scale (MFIS) were significantly reduced in the study by Grossman et al. [40] at both intervention completion in the overall population, as well as in subgroup analyses of those with pre-intervention impairment. Beneficial effect was maintained in the overall group at six-months, as well as in those with pre-intervention impairment. Tavee et al. [42] also reported significant change on MFIS at study completion. Fatigue was non-significantly reduced on POMS in the Mills and Allen [41] study see Table 5.

**Psychosocial outcomes**
Grossman et al. [40] measured both disease-specific (Hamburg Quality of Life Questionnaire in Multiple Sclerosis; HAQUAMS) and generic HRQOL (Profile of Health-Related Quality of Life in Chronic Disorders; PQOLC), with PQOLC being significantly improved at study completion in the overall group and in subgroup analyses for those with pre-intervention impairment, as well as at six-month follow up in overall group and in subgroup analyses. Similarly, HAQUAMS was significantly improved at completion in the overall group and in subgroup analyses in those with pre-intervention impairment, as well as at six-month follow up in overall group and subgroup analyses. Mills and Allen [41] report an overall trend towards general symptom improvement, but did not justify this statistically. Tavee et al. [42] did not report population-specific results for the Short Form-36 (SF-36). See Table 6.

**Methodological quality of included papers**
Quality was assessed using the Cochrane Collaboration tool for Risk of Bias [39]. Of the 3 studies, only Grossman et al. [40] adequately describe evidence of sequence generation at the randomisation stage. Allocation concealment was most convincingly implemented by Grossman et al. [40], where the investigator was fully blinded to patient information, but this was not clearly described by Mills and Allen [41]; Tavee et al. [42] appear to have collected a control group independently of those expressing a desire to take part in the intervention group. Only Grossman et al. [40] described blinding of outcome assessors. All three authors described incomplete outcome data, including attrition rates, but only Grossman et al. [40] included this intention to treat and attrition data in the statistical analysis. There was no substantive evidence for selective outcome reporting in any of the studies,

### Table 4 Mental health outcomes

| Study                  | Outcome (measure) | Post intervention effect size (p) | Follow up effect size (p) and time point |
|------------------------|-------------------|----------------------------------|----------------------------------------|
| Grossman et al. [40]   |                   |                                  |                                        |
| Full intervention group| Anxiety (STAI)    | 0.39 (0.00006)                  | 0.36 (0.02) at six months              |
| Sub-group analysis     |                   | 1.00 (0.002)                    | 0.64 (0.05) at six months              |
| Full intervention group| Depression (CES-D)| 0.65 (0.00001)                 | 0.36 (0.03) at six months              |
| Sub-group analysis     |                   | 1.06 (0.00002)                  | 0.66 (0.03) at six months              |
| Mills and Allen [41]   |                   |                                  |                                        |
| Anxiety (POMS)         |                   | p > 0.05*                       | p > 0.05*                             |
| Depression (POMS)      |                   | p < 0.01*                       | NR                                     |

1. STAI - Spielberger Trait Anxiety Index; 2. CES-D - Centre for Epidemiological Studies Depression Scale; 3. POMS - Profile of Mood States.

*Effect size not recorded.
although Mills and Allen [41] omitted data on mood recording via Profile of Mood States (POMS), which is described elsewhere [43]. Overall, only the study by Grossman et al. [40] can be considered of high methodological quality (see Table 7).

Discussion

This systematic review on the use of MBIs in people with MS identified three studies eligible for inclusion, which were varied in nature, with only one of the studies being adequately powered to calculate meaningful effect sizes (n = 150). Attrition rates across the studies were variable, and the reasons for this are unclear. The MBIs used in the studies were heterogeneous. Two papers described a protocol comparable to MBSR, but stemming from Qi Gong practices; the other study closely resembled a more standardised version of MBI [34]. Two of the interventions were applied in a hospital based group setting; one was individualised and delivered one to one in patients’ homes. There were a variety of measures of interest recorded. However, none of the studies focussed on our primary outcome of interest: perceived stress.

Results from the three studies are encouraging in the domains of mental health and HRQOL. Improvements in HRQOL, anxiety, depression, and fatigue remained statistically significant at six-month follow up in the Grossman et al. [40] study, albeit with diminished effect sizes; standing balance remained significantly improved at three-month follow up in the Mills and Allen [41] study. There were no adverse events reported.

Strengths of this review

This review employed a rigorous methodological strategy to search and appraise the research literature involving MBIs in people with MS. Three reviewers were involved in the screening and appraisal of studies suitable for inclusion, with further discussion taking place, as required. Quality was assessed in accordance with the Cochrane Collaboration guidance.

Limitations of this review

The fact that MBIs originate from ancient oriental traditions may bias the results, in that, due to resource constraints, our review was limited to papers published in English. The low methodological quality of two studies, and the overall heterogeneous nature of the studies, precluded quantitative meta-analysis.

Strengths and limitations of the included papers

Grossman et al. [40] produced a well designed RCT, with adequate numbers being included to allow power calculations. Their strict inclusion/exclusion criteria, and widely recognisable form of MBI, delivered by experienced, certified trainers, with pre-post and three-month follow up measures being collected, allows a degree of confidence when reviewing their findings. Mills and Allen [41] and Tavee et al. [42] conducted studies that were of lower methodological quality, with small sample sizes, and less well-defined intervention standards. There was no randomisation employed by Tavee et al. [42]. Comparing all three studies, there is considerable heterogeneity with respect to

Table 5 Physical outcomes

| Study                        | Outcome (measure)       | Post intervention effect size (p) | Follow up effect size (p) and time point |
|------------------------------|-------------------------|----------------------------------|-----------------------------------------|
| Grossman et al. [40]         | Full intervention group | Fatigue (MFIS)                   | 0.41 (0.0001)                           |
|                              |                         |                                  | 0.38 (0.001)                           |
|                              | Sub-group analysis      | Fatigue (POMS)                   | 1.27 (0.0005)                           |
|                              |                         |                                  | 1.09 (0.02) at six months               |
| Mills and Allen [41]         | Fatigue (POMS)          | p > 0.05*                        |                                        |
|                              | Single leg standing balance | p < 0.05*                    |                                        |
|                              |                         |                                  | p < 0.05* at three months               |
| Tavee et al. [42]            | Fatigue (MFIS)          | p = 0.035*                       |                                        |
|                              | Pain (VAS)              | p = 0.031*                       |                                        |
|                              | PDDS                    | p > 0.05*                        |                                        |

1. MFIS - Modified Fatigue Index Scale; 2. POMS - Profile of Mood States; 3. VAS - Visual Analogue Scale for pain; 4. PDDS - Patient Determined Disease Steps; 5. NR - Not recorded; *Effect size not recorded.

Table 6 Quality of life outcomes

| Study                        | Measure       | Post intervention effect size (p) | Follow up effect size (p) and time point |
|------------------------------|---------------|----------------------------------|-----------------------------------------|
| Grossman et al. [40]         | HAQUAMS       | 0.43 (0.0002)                    | 0.28 (0.04) at six months               |
|                              | PQOLC         | 0.86 (0.00000001)                | 0.51 (0.03) at six months               |
|                              | Sub-group analysis | HAQUAMS       | 1.01 (0.0001)                           |
|                              |               |                                  | 0.58 (0.04) at six months               |
|                              |               |                                  |                                        |
|                              | PQOLC         | 1.71 (0.00000001)                | 0.51 (0.003) at six months              |

1. HAQUAMS - Hamburg Quality of Life Questionnaire in Multiple Sclerosis (German); 2. PQOLC - Profile of Health-related Quality of Life in chronic disorders (German).
populations, interventions and outcome measures, and almost no meaningful information on the effects on different socioeconomic groups. Limited information was provided regarding different disease phenotypes and ‘stages’ of illness. Furthermore, little evidence is available about economic costs/benefits of the MBIs in this group, making drawing conclusions about any individual MBI technique in this population in general problematic. As such, these results should be treated with caution.

Implications for research
Future studies of MBIs in people with MS should be of a larger scale, employing robust methodological techniques. They should examine physical and psychological measures; different disease phenotypes, at various defined stages of disease progression, of varied functional status; and should address important questions around feasibility, acceptability and appropriateness in diverse ethnic groups; as well as economic concerns such as health care utilisation and cost effectiveness. For specialist groups, such as people with MS, it may be worth examining whether having classes run by specialist trainers’ (i.e. health professionals) rather than ‘generic’ MBI trainers has any specific advantages/benefits.

Correlating findings with neuropsychological, biomarker and clinical imaging evidence would also be very informative. Given the widely varying attrition rates reported, qualitative research should also be employed to gather information on the broad acceptability of MBIs from the perspective of people with MS. Such research could also explore perceived stress and self-efficacy, as discussed previously.

Implications for practice
MBIs may have utility in the MS clinical population, particularly for mental health conditions, such as anxiety and depression, as well as physical function. There is no overt evidence of harm.

Conclusions
Although the evidence is limited, this review indicates that MBIs can hold benefit for people with MS, specifically in terms of quality of life, mental health, and some physical aspects of the condition. It is unclear at this time whether these results are generalisable to different ethnic groups; both genders; all age groups; different disease phenotypes; and diverse socio-economic groups. There is no evidence regarding health service utilisation costs. It also remains unclear what benefit MBIs may hold for people with more advanced MS. Further high quality studies are needed to clarify the feasibility, practicality, acceptability, health and psychosocial benefits of MBIs for people with MS.

### Additional files

- **Additional file 1:** Search history: OVIDsp - MEDLINE with Full Text 3/5/13 - pdf.
- **Additional file 2:** Excluded studies - pdf.

### Competing interests
The authors declare that they have no competing interests.

### Author’s contributions
This systematic review was conceived by RS, SM, FM, ML and JB. RS registered this project with PROSPERO and took the lead for the review. RS conducted all database searches. RS, SB and JB carried out the screening of studies identified on database searching. RS authored the manuscript; whilst SM, FM, ML and JB all provided critical review and input into manuscript writing. All authors read and approved the final manuscript.

### Author details

1. General Practice and Primary Care, Institute of Health and Wellbeing, University of Glasgow, Glasgow, G12 9LX, Scotland, UK.
2. Institute for Applied Health Research/School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, G4 0BA, Scotland, UK.

Received: 15 October 2013 Accepted: 14 January 2014
Published: 17 January 2014

### References

1. Franklin RJM, Ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 2012, 8(11):624–634.
2. Scaffari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010, 133(7):1914–1929.
3. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. The Lancet Neurol 2008, 7(12):1139–1151.
4. Young CA. Factors predisposing to the development of multiple sclerosis. QJM 2011, 104(5):383–386.
5. Dennison L, Moss-Morris R, Chalder T. A review of psychological correlates of adjustment in patients with multiple sclerosis. Clin Psychol Rev 2009, 29(2):141–153.
6. Damasceno A, Von Glehn F, Brandão CO, Damasceno BP, Cendes F: Prognostic indicators for long-term disability in multiple sclerosis patients. J Neurol Sci 2002, 213(1–2):29–33.

7. Boland P, Levack WM, Hudson S, Bell EM: Coping with multiple sclerosis as a couple: ‘peaks and troughs’–an interpretative phenomenological exploration. Disabil Rehabil 2012, 34(16):1367–1375.

8. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(1):121–127.

9. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69(2):292–302.

10. McClone P, Heslin M, Knapp M, Bull P, Thompson A: Multiple Sclerosis in the UK. Pharmacoecon 2008, 26(10):847–860.

11. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T: Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008, 14(6):1091–1098.

12. Dallmeijer AJ, Beckerman H, de Groot V, van de Port IG, Lankhorst GJ, Dekker J: Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med 2009, 41(5):322–326.

13. Warren SA, Turpin KV, Pohar SL, Jones CA, Warren K: Comorbidity amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 2010, 17(9):1215–1219.

14. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T: The burden of mental comorbidity in multiple sclerosis: frequent, undiagnosed, and undertreated. Mult Scler 2009, 15(3):385–392.

15. Klenav G, Jacobsen C, Aarseth J, Myhr KM, Nyland H, Glad S, et al: Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurol Scand 2013, 129(1):21–26.

16. McGuigan C, Hutchinson M: Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol 2006, 253(2):219–223.

17. Chwastik LA, Ende DM: Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am 2007, 30(4):803–817.

18. Trojan DA, Arnold D, Collet J-P, Shapiro S, Bar-On A, Robinson A, et al: Fatigue in multiple sclerosis: association with disease-related, behavioural and psychosocial factors. Mult Scler 2007, 13(8):985–995.

19. Bol Y, Duits AA, Hupperts RM, Vlaeyen JW, Verheij FR: The psychology of fatigue in patients with multiple sclerosis: a review. J Psychosom Res 2009, 66(1–3):11–17.

20. Mohr DC, Hall SL, Julian L, Cox D, Pelletier D: Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004, 328(7442):731.

21. Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, et al: A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology 2012, 79(5):412–419.

22. Penn JD, Zimmerman A: Review: Brain—immune communication psychoneuroimmunology of multiple sclerosis. Mult Scler 2008, 14(16):1–21.

23. Thomas P, Thomas S, Hillier C, Galvin K, Baker R: Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev 2006, 1:1–53.

24. Kabat-Zinn J: Wherever you go, there you are: Mindfulness meditation in everyday life: Hyperion. 1994.

25. Miller JJ, Fletcher K, Kabat-Zinn J: Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. Gen Hosp Psychiatry 1995, 17(3):192–200.

26. Kabat-Zinn J, Lipworth L, Burney R, Sellers W: Four-year follow-up of a meditation-based program for the self-regulation of chronic pain: treatment outcomes and compliance. The Clinical Journal of Pain 1986, 2(1):109–174.

27. Piet J, Hougaard E: The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clin Psychol Rev 2011, 31(6):1032–1040.

28. Lawrence M, Booth J, Mercer S, Crawford E: A systematic review of the benefits of mindfulness-based interventions following transient ischemic attack and stroke. Int J Stroke 2013, 8(6):465–474.

29. Robinson FP, Mathews HL, Witek-Janusek L: Psycho-endocrine-immune response to mindfulness-based stress reduction in individuals infected with the human immunodeficiency virus: a quasi-experimental study. The J Altern & Complement Med 2003, 9(5):683–694.

30. Davidson RJ, Kabat-Zinn J, Schumacher J, Rosenkranz M, Muller D, Santorelli SF, et al: Alterations in brain and immune function produced by mindfulness meditation. Psychosom Med 2003, 65(4):564–570.

31. Carlson LE, Speca M, Patel KD, Goodey E: Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 2004, 29(4):448–474.

32. Holzel BK, Lazar SW, Gard T, Schuman-Olivier Z, Vago DR, Ott U: How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective. Perspect Psychol Sci 2011, 6(1):537–559.

33. Kabat-Zinn J: Full catastrophe living: Using the wisdom of your body and mind to face stress, pain, and illness: Delta. 2009.

34. Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA: Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000, 68(6):615.

35. Kahl KG, Winter L, Schweiger U: The third wave of cognitive behavioural therapies: what is new and what is effective? Curr Opin Psychiatry 2012, 25(6):522–528. doi:10.1097/YCO.0b013e32835b531.

36. Reck B, Wilson MC, Nichikawa J, Hayward RS: The well-built clinical question: a key to evidence-based decisions. ACP J Club 1995, 123(3):A12–A13.

37. Reviews UOYCF, D, Akers J: Systematic reviews: CRO’s guidance for undertaking reviews in health care: Centre for Reviews and Dissemination. 2009.

38. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ: British Medical Journal 2011, 343:d5928.

39. Grossman P, Kappos L, Genestie H, D’Souza M, Mohr DC, Penner IK, et al: MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 2010, 75(13):1141–1149.

40. Mills N, Allen J: Mindfulness of movement as a coping strategy in multiple sclerosis: a pilot study. Gen Hosp Psychiatry 2000, 22(6):425–431.

41. Tavee J, Rensel W, Pope Panchon S, Stone L: Effects of meditation on pain and quality of life in multiple sclerosis and polynuropathy: a controlled study. Int J MS Care 2011, 13(2):163–168.

42. Mills N, Allen J, Carey-Morgan S: Does Tai Chi/Qi Gong help patients with multiple sclerosis? J Bodyw Mov Ther 2000, 4(1):39–48.